Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 20,548
Companies: 1,769
Drugs tracked: 4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

same excipients except no hypromellose, PREDNISONE , SAR445761 - belumosudil, PREDNISOLONE

A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa

A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouth

Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

Amlitelimab, Amlitelimab matching placebo to test product

Amlitelimab, Amlitelimab matching placebo to test product

Amlitelimab, Placebo

An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301

Balinatunfib, Not the same excipients as test

Dexamethason 4 mg JENAPHARM®, evorpacept, Isatuximab, Dexamethason 8 mg JENAPHARM®, Isatuximab

Dexamethason 8 mg JENAPHARM®, SAR445761 - belumosudil, Isatuximab, Isatuximab, Dexamethason 4 mg JENAPHARM®

Frexalimab, Matched Placebo for Test

INBRX-101 Concentrate for Solution for Infusion 50mg/ml

Isatuximab, Dexamethason 8 mg JENAPHARM®, Dexamethason 4 mg JENAPHARM®, Isatuximab

Isatuximab, Kyprolis 60 mg powder for solution for infusion, METHYLPREDNISOLONE , MONTELUKAST , DexaGalen® 8 mg injekt Injektionslösung, DIPHENHYDRAMINE , Dexamethason 4 mg JENAPHARM®, Dr. Reddy's Carfilzomib, PARACETAMOL

Itepekimab

Itepekimab, Matched placebo for test product

Match Placebo to Test Product, SAR441566, SAR441566

Match placebo to test product, Balinatunfib

Match placebo to test product, METHOTREXATE , SAR441566, SAR441566

Frequently asked questions